Introduction {#s001}
============

Venous thromboembolism (VTE) is a hospital-acquired condition that has a significant impact on morbidity, mortality, and hospital costs. Between 100,000 and 180,000 deaths per year in the United States may be directly or indirectly related to all-cause VTE, with the total incidence being between 350,000 and 600,000.^[@B1]^ Approximately half of these are hospital-acquired VTE.^[@B2]^ Despite advances in diagnosis and treatment, VTE persists as a common cause of death in the inpatient setting.^[@B3]^

Although VTE continues to be a significant source of morbidity and mortality, there have been many safe and cost-effective interventions aimed at reducing VTE occurrence.^[@B4]^ Inpatient prophylaxis is multimodal and falls into three major categories: pharmacological, mechanical, and ambulatory. The most well-studied pharmacoprophylaxis medications are heparin and enoxaparin^[@B5],[@B6]^; new direct oral anticoagulants have been primarily studied in joint replacement surgery and are also effective in preventing symptomatic VTE.^[@B7]^ Mechanical therapies, including thromboembolic deterrent (TED) stockings, and intermittent pneumatic compression (IPC) devices, have also been shown to decrease VTE risk.^[@B8],[@B9]^ Finally, multiple studies have indicated that postoperative ambulation, along with concomitant pharmacological and mechanical prophylaxis, reduces the incidence of VTE, improves postoperative outcomes, and decreases length of stay (LOS) in thoracic, cardiac, abdominal, and orthopedic surgical patients.^[@B10]^ Furthermore, institutions with formal ambulation programs have reported enhanced adherence to ambulation protocols by patients and hospital staff.^[@B13]^ Many guidelines regarding VTE prophylaxis include explicit recommendations stating that hospitals and surgical services should synthesize a formal VTE prophylaxis algorithm that includes a risk assessment tool and a specified regimen for VTE prevention.^[@B17]^

Our surgical department is a member of the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP), which releases semiannual rankings of each participating hospital and service on the basis of adverse event rates. Our institution\'s hepatopancreaticobiliary surgery service (HPBS), which primarily performs pancreatic surgical procedures, has followed a robust and aggressive VTE prophylaxis pathway ([Fig. 1](#f1){ref-type="fig"}) that has remained largely unchanged over the past 10 years. The HPBS has historically been a low outlier in symptomatic VTE events as determined by the ACS NSQIP, consistently performing in the more favorable bottom decile of all participating institutions.

![HPBS VTE prevention pathway. Overview of the interventions (on the left) and oversight measures (on the right) employed preoperatively, intraoperatively, and postoperatively in the inpatient and outpatient settings. HPBS, hepatopancreaticobiliary surgery service; VTE, venous thromboembolism.](pancan.2020.0002_figure1){#f1}

Given the perceived low rate of symptomatic VTE in the HPBS as suggested by NSQIP semiannual reports, we sought to determine whether the low VTE rate in the HPBS patients is due to the specific interventions implemented by the HPBS, or underlying differences in preoperative patient characteristics. To achieve this goal, we used a cohort-matched multivariate analysis, comparing the NSQIP participant user file (PUF) and our institutional data for a 6-year period.

Materials and Methods {#s002}
=====================

Identification of patient populations {#s003}
-------------------------------------

After acquiring institutional review board approval, we queried the ACS NSQIP PUF from 2011 to 2016 and our institutional data for the HPBS during the same time period for all patients undergoing pancreatic procedures as captured by current procedural terminology (CPT) codes 48140, 48145, 48150, 48153, 48154, and 48155.[^\*^](#fn2){ref-type="fn"} As our institutional data are reported to the ACS for inclusion in the NSQIP PUF, we were able to identify institutional observations within the PUF and mark them as such for the purpose of comparing HPBS and non-HPBS cases. HPBS cases were identified in the PUF by using our institutional data to find observations with perfect matches in multiple variables.

Creation of the matched cohort {#s004}
------------------------------

Owing to the likelihood of selection bias in a retrospective study such as this, we used a matching algorithm to create HPBS and national cohorts with equivalent patient populations as determined by multiple preoperative factors (as given in [Table 1](#tb1){ref-type="table"}). To achieve this, we applied a coarsened exact matching procedure, which coarsens the data through the creation of meaningful strata, and then attempts to match each observation.^[@B21]^ The matching process was done without replacement. The result is matched cohorts with an equal number of patients with equivalent preoperative parameters in each group ([Table 1](#tb1){ref-type="table"}).

###### 

Preoperative Factors and Comorbidities

  Parameter                            Aggregate cohort, *n* (%)   Matched cohort, *n* (%)                                                                        
  ------------------------------------ --------------------------- ------------------------- ------------------------------------------ ------------ ------------ -------
  Age \>75 years                       174 (20.5)                  5720 (16.1)               0.001^[\*](#tf1){ref-type="table-fn"}^     153 (19.1)   153 (19.1)   1.000
  Male                                 436 (51.3)                  17,900 (50.3)             0.568                                      410 (51.1)   410 (51.1)   1.000
  Female                               414 (48.7)                  17,685 (49.7)             393 (48.9)                                 393 (48.9)                
  Black                                71 (8.4)                    3299 (9.3)                0.361                                      65 (8.1)     65 (8.1)     1.000
  Asian                                19 (2.2)                    1254 (3.5)                0.043^[\*](#tf1){ref-type="table-fn"}^     17 (2.1)     17 (2.1)     1.000
  Hawaiian                             0 (0.0)                     81 (0.2)                  0.164                                      0 (0.0)      0 (0.0)      ---
  Unknown race                         20 (2.4)                    3093 (8.7)                \<0.001^[\*](#tf1){ref-type="table-fn"}^   16 (2.0)     16 (2.0)     1.000
  White                                679 (79.9)                  27,419 (77.1)             0.052                                      662 (82.4)   662 (82.4)   1.000
  Indian                               0 (0.0)                     119 (0.3)                 0.091                                      0 (0.0)      0 (0.0)      ---
  BMI \<18                             16 (1.9)                    1081 (3.0)                0.051                                      14 (1.7)     14 (1.7)     1.000
  BMI 25--30                           528 (62.1)                  22,583 (63.5)             0.421                                      501 (62.4)   501 (62.4)   1.000
  BMI \>30                             239 (28.1)                  10,424 (29.3)             0.457                                      227 (28.3)   227 (28.3)   1.000
  Transferred from non-home facility   20 (2.4)                    1122 (3.2)                0.186                                      9 (1.1)      9 (1.1)      1.000
  Diabetes                             221 (26.0)                  9040 (25.4)               0.693                                      205 (25.5)   205 (25.5)   1.000
  Current smoker                       130 (15.3)                  7017 (19.7)               0.001^[\*](#tf1){ref-type="table-fn"}^     117 (14.6)   117 (14.6)   1.000
  Dyspnea                              80 (9.4)                    2138 (6.0)                \<0.001^[\*](#tf1){ref-type="table-fn"}^   65 (8.1)     65 (8.1)     1.000
  Functional status                    1 (0.1)                     317 (0.9)                 0.008^[\*](#tf1){ref-type="table-fn"}^     1 (0.1)      1 (0.1)      1.000
  On a ventilator                      1 (0.1)                     45 (0.1)                  0.943                                      0 (0)        0 (0)        ---
  COPD                                 15 (1.8)                    1623 (4.6)                \<0.001^[\*](#tf1){ref-type="table-fn"}^   13 (1.6)     13 (1.6)     1.000
  Ascites                              0 (0.0)                     144 (0.4)                 0.063                                      0 (0.0)      0 (0.0)      ---
  CHF                                  0 (0.0)                     137 (0.4)                 0.070                                      0 (0.0)      0 (0.0)      ---
  HTN                                  474 (55.8)                  18,877 (53.0)             0.117                                      449 (55.9)   449 (55.9)   1.000
  Renal failure                        0 (0.0)                     47 (0.1)                  0.289                                      0 (0.0)      0 (0.0)      ---
  On dialysis                          3 (0.4)                     149 (0.4)                 0.769                                      0 (0.0)      0 (0.0)      ---
  Preoperative wound infection         2 (0.2)                     223 (0.6)                 0.150                                      1 (0.1)      1 (0.1)      1.000
  Steroid use                          16 (1.9)                    1065 (3.0)                0.059                                      11 (1.4)     11 (1.4)     1.000
  Recent weight loss                   120 (14.1)                  4702 (13.2)               0.442                                      106 (13.2)   106 (13.2)   1.000
  Bleeding disorder                    15 (1.8)                    1082 (3.0)                0.031^[\*](#tf1){ref-type="table-fn"}^     11 (1.4)     11 (1.4)     1.000
  Recent transfusion                   4 (0.5)                     437 (1.2)                 0.046^[\*](#tf1){ref-type="table-fn"}^     0 (0.0)      0 (0.0)      ---
  Preoperative sepsis                  1 (0.1)                     575 (1.6)                 0.001^[\*](#tf1){ref-type="table-fn"}^     0 (0.0)      0 (0.0)      ---
  Emergency procedure                  1 (0.1)                     246 (0.7)                 0.044^[\*](#tf1){ref-type="table-fn"}^     0 (0.0)      0 (0.0)      ---
  ASA \>2                              592 (69.6)                  26,025 (73.1)             0.024^[\*](#tf1){ref-type="table-fn"}^     561 (69.9)   561 (69.9)   1.000
  Disseminated cancer                  19 (2.2)                    1917 (5.4)                \<0.001^[\*](#tf1){ref-type="table-fn"}^   17 (2.1)     17 (2.1)     1.000

Indicates a significant result.

ASA, American Society of Anesthesiologists; BMI, body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; HPBS, hepatopancreaticobiliary surgery service; HTN, hypertension; NSQIP, National Surgical Quality Improvement Program.

Statistical analysis {#s005}
--------------------

Statistical analysis was performed using Stata v13 (StataCorp). All analyses were performed on both the aggregate and matched cohorts. VTE was defined as any deep vein thrombosis (DVT) or pulmonary embolus (PE) reported in the PUF. Within NSQIP, a reportable DVT or PE is a new thrombus within 30 days of surgery necessitating treatment. Descriptive and comparative analyses of the HPBS and national cohorts were done using a chi-square test for categorical variables and *t*-test with equal variance for continuous variables. The same method was also used to determine whether or not VTE rates were significantly different between the national cohort and the HPBS patients, as well as to perform a secondary analysis of additional perioperative complications. Univariate analysis of baseline risk factors for VTE was performed using logistic regression to determine odds ratios (ORs), with a *p* \< 0.05 being considered statistically significant. Inclusion in the multivariate analysis was reserved for those factors yielding a *p* \< 0.1 in the univariate analysis.

Results {#s006}
=======

In total, 36,489 pancreatic operations were identified in the 2011--2016 ACS NSQIP PUFs. Within our institution, the HPBS performed operations on 1046 patients in that same time period, of which 853 (82.0%) were coded as a pancreatic excision. Of those patients, 850 (99.6%) were successfully identified within the PUF, accounting for 2.3% of the pancreatic operations reported nationally. Of note, no VTE event occurred in any of the three unidentified observations. During the identification of the HPBS patients within the PUF, 54 (0.1%) national observations were excluded to optimize the identification process. This resulted in 36,435 total cases (850 HPBS and 35,585 national).

Overall, 1266 patients (3.4%) had a reported symptomatic VTE event; the HPBS had a significantly lower rate of symptomatic VTE than the national cohort (*p* = 0.018); 17/850 (2.0%) and 1249/35,585 (3.5%), respectively ([Table 2](#tb2){ref-type="table"}). As given in [Table 3](#tb3){ref-type="table"}, in the aggregate cohort, univariate analysis identified 17 parameters significantly associated with VTE (*p* \< 0.05). To account for the confounding effects that each variable can have on outcomes, a multivariate logistic regression was run, controlling for the 17 variables that achieved statistical significance in the univariate analysis as well as two additional variables that had a p-value of \<0.1. This analysis ([Table 3](#tb3){ref-type="table"}) indicated that four factors were significantly associated with an elevated likelihood of VTE: age \>75 years, body mass index (BMI) \>30, history of bleeding disorder, and American Society of Anesthesiologists (ASA) class \>2. Conversely, Asian race, current smoking, and procedure performed by the HPBS independently conferred a lower likelihood of developing a VTE postoperatively.

###### 

Intraoperative and Postoperative Parameters

  Parameter                                                                 Aggregate cohort, *n* (%)   Matched cohort, *n* (%)                                                                              
  ------------------------------------------------------------------------- --------------------------- ------------------------- ------------------------------------------ --------------- --------------- ------------------------------------------
  Operative time (minutes; mean ± SD)^[a](#tf3){ref-type="table-fn"}^       397.6 ± 117.5               322.4 ± 142.3             \<0.001^[\*](#tf5){ref-type="table-fn"}^   397.5 ± 118.0   316.9 ± 137.0   \<0.001^[\*](#tf5){ref-type="table-fn"}^
  Total hospital LOS (days; mean ± SD)^[a](#tf3){ref-type="table-fn"}^      8.3 ± 6.2                   10.8 ± 9.3                \<0.001^[\*](#tf5){ref-type="table-fn"}^   8.3 ± 6.3       10.3 ± 7.4      \<0.001^[\*](#tf5){ref-type="table-fn"}^
  Wound infection                                                           155 (18.2)                  7217 (20.3)               0.142                                      148 (18.4)      161 (20.0)      0.411
   Superficial                                                              39 (4.6)                    2533 (7.1)                0.004^[\*](#tf5){ref-type="table-fn"}^     35 (4.4)        52 (6.5)        0.079
   Deep                                                                     6 (0.7)                     737 (2.1)                 0.005^[\*](#tf5){ref-type="table-fn"}^     6 (0.7)         18 (2.2)        0.014^[\*](#tf5){ref-type="table-fn"}^
   Organ/space                                                              117 (13.8)                  4335 (12.2)               0.164                                      113 (14.1)      99 (12.3)       0.302
   Dehiscence                                                               1 (0.1)                     433 (1.2)                 0.004^[\*](#tf5){ref-type="table-fn"}^     1 (0.1)         8 (1.0)         0.019^[\*](#tf5){ref-type="table-fn"}^
  Respiratory complication                                                  27 (3.2)                    2305 (6.5)                \<0.001^[\*](#tf5){ref-type="table-fn"}^   25 (3.1)        46 (5.7)        0.011^[\*](#tf5){ref-type="table-fn"}^
   Pneumonia                                                                18 (2.1)                    1466 (4.1)                0.004^[\*](#tf5){ref-type="table-fn"}^     17 (2.1)        23 (2.9)        0.337
   Ventilator dependence                                                    16 (1.9)                    1164 (3.3)                0.024^[\*](#tf5){ref-type="table-fn"}^     15 (1.9)        20 (2.5)        0.393
   Reintubation                                                             17 (2.0)                    1334 (3.7)                0.008^[\*](#tf5){ref-type="table-fn"}^     16 (2.0)        32 (4.0)        0.019^[\*](#tf5){ref-type="table-fn"}^
  VTE^[b](#tf4){ref-type="table-fn"}^                                       17 (2.0)                    1249 (3.5)                0.018^[\*](#tf5){ref-type="table-fn"}^     17 (2.1)        31 (3.9)        0.040^[\*](#tf5){ref-type="table-fn"}^
   DVT                                                                      11 (1.3)                    923 (2.6)                 0.052                                      11 (1.4)        23 (2.9)        0.096
   PE                                                                       7 (0.8)                     437 (1.2)                 0.288                                      7 (0.9)         13 (1.6)        0.177
  Time to VTE formation (days; mean ± SD)^[a](#tf3){ref-type="table-fn"}^   17.1 ± 5.0                  13.2 ± 8.0                0.105                                      17.1 ± 5.0      11.9 ± 5.9      0.019^[\*](#tf5){ref-type="table-fn"}^
  Cardiac arrest                                                            2 (0.2)                     391 (1.1)                 0.016^[\*](#tf5){ref-type="table-fn"}^     2 (0.2)         6 (0.7)         0.156
  Myocardial infarction                                                     1 (0.1)                     367 (1.0)                 0.008^[\*](#tf5){ref-type="table-fn"}^     1 (0.1)         8 (1.0)         0.019^[\*](#tf5){ref-type="table-fn"}^
  Sepsis                                                                    61 (7.2)                    2854 (8.0)                0.370                                      58 (7.2)        54 (6.7)        0.695
  Reoperation                                                               19 (2.2)                    1875 (5.3)                \<0.001^[\*](#tf5){ref-type="table-fn"}^   17 (2.1)        43 (5.4)        0.001^[\*](#tf5){ref-type="table-fn"}^
  Readmission                                                               10 (1.2)                    639 (1.8)                 0.055                                      10 (1.2)        18 (2.2)        0.079

Calculated using *t*-test of equal variance.

In the aggregate, 1 patient in the HPBS cohort and 111 patients in the NSQIP cohort had both a DVT and PE; in the matched data set, 1 patient in the HPBS cohort and 5 patients in the NSQIP cohort had both a DVT and PE.

Indicates a significant result.

DVT, deep vein thrombosis; LOS, length of stay; PE, pulmonary embolus; SD, standard deviation; VTE, venous thromboembolism.

###### 

Univariate and Multivariate Analysis of Aggregate Cohort Venous Thromboembolism Risk

  Parameter                            Univariate (*n* = 36,435)   Multivariate (*n* = 36,435)                                                                     
  ------------------------------------ --------------------------- ----------------------------- ------------------------------------------ ------- -------------- ------------------------------------------
  Age \>75 years                       1.247                       1.082--1.438                  0.002^[\*](#tf9){ref-type="table-fn"}^     1.223   1.055--1.418   0.007^[\*](#tf9){ref-type="table-fn"}^
  Sex                                  1.151                       1.029--1.288                  0.014^[\*](#tf9){ref-type="table-fn"}^     1.117   0.997--1.252   0.057
  Black                                0.970                       0.798--1.180                  0.760                                      ---     ---            ---
  Asian                                0.390                       0.244--0.623                  \<0.001^[\*](#tf9){ref-type="table-fn"}^   0.485   0.299--0.789   0.004^[\*](#tf9){ref-type="table-fn"}^
  Hawaiian                             1.069                       0.337--3.390                  0.910                                      ---     ---            ---
  Unknown race                         0.905                       0.735--1.115                  0.348                                      ---     ---            ---
  White                                1.239                       1.076--1.427                  0.003^[\*](#tf9){ref-type="table-fn"}^     1.126   0.972--1.305   0.113
  Indian                               0.718                       0.228--2.261                  0.571                                      ---     ---            ---
  BMI \<18 kg/m^2^                     1.081                       0.787--1.485                  0.629                                      ---     ---            ---
  BMI 25--30 kg/m^2^                   1.379                       1.220--1.559                  \<0.001^[\*](#tf9){ref-type="table-fn"}^   1.122   0.972--1.296   0.117
  BMI \>30 kg/m^2^                     1.509                       1.344--1.694                  \<0.001^[\*](#tf9){ref-type="table-fn"}^   1.294   1.216--1.598   \<0.001^[\*](#tf9){ref-type="table-fn"}^
  Transferred from non-home facility   1.228                       0.914--1.648                  0.173                                      ---     ---            ---
  Diabetes                             1.098                       0.968--1.246                  0.145                                      ---     ---            ---
  Current smoker                       0.781                       0.671--0.909                  0.001^[\*](#tf9){ref-type="table-fn"}^     0.815   0.698--0.953   0.010^[\*](#tf9){ref-type="table-fn"}^
  Dyspnea                              1.086                       0.865--1.362                  0.478                                      ---     ---            ---
  Functional status \>1                1.588                       1.008--2.500                  0.046^[\*](#tf9){ref-type="table-fn"}^     1.280   0.806--2.033   0.295
  On a ventilator                      3.397                       1.340--8.612                  0.010^[\*](#tf9){ref-type="table-fn"}^     1.675   0.593--4.728   0.330
  COPD                                 1.215                       0.947--1.559                  0.127                                      ---     ---            ---
  Ascites                              2.082                       1.092--3.968                  0.026^[\*](#tf9){ref-type="table-fn"}^     1.668   0.861--3.231   0.130
  CHF                                  2.197                       1.151--4.192                  0.017^[\*](#tf9){ref-type="table-fn"}^     1.666   0.865--3.207   0.127
  HTN                                  1.095                       0.979--1.226                  0.114                                      ---     ---            ---
  On dialysis                          1.142                       0.504--2.589                  0.750                                      ---     ---            ---
  Wound infection                      1.571                       0.876--2.817                  0.130                                      ---     ---            ---
  Steroid use                          1.302                       0.970--1.749                  0.079                                      1.215   0.903--1.635   0.198
  Recent weight loss                   0.871                       0.732--1.036                  0.118                                      ---     ---            ---
  Bleeding disorder                    1.698                       1.306--2.208                  \<0.001^[\*](#tf9){ref-type="table-fn"}^   1.482   1.136--1.934   0.004^[\*](#tf9){ref-type="table-fn"}^
  Recent transfusion                   1.829                       1.234--2.711                  0.003^[\*](#tf9){ref-type="table-fn"}^     1.412   0.920--2.169   0.115
  Preoperative sepsis                  1.429                       0.973--2.098                  0.068                                      1.066   0.696--1.632   0.770
  Emergency procedure                  1.936                       1.163--3.223                  0.011^[\*](#tf9){ref-type="table-fn"}^     1.442   0.816--2.548   0.208
  ASA \>2                              1.503                       1.307--1.729                  \<0.001^[\*](#tf9){ref-type="table-fn"}^   1.366   1.184--1.575   \<0.001^[\*](#tf9){ref-type="table-fn"}^
  Disseminated cancer                  1.279                       1.020--1.603                  0.033^[\*](#tf9){ref-type="table-fn"}^     1.229   0.979--1.543   0.076
  Procedure performed by HPBS          0.561                       0.346--0.910                  0.019^[\*](#tf9){ref-type="table-fn"}^     0.572   0.352--0.928   0.024^[\*](#tf9){ref-type="table-fn"}^

Renal failure was not included in the univariate or multivariate analysis as there were no events noted in the HPBS cohort.

--- indicates that a variable was not included in multivariate analysis.

Indicates a significant result.

CI, confidence interval; OR, odds ratio.

The matching algorithm yielded 803 patients in each cohort for analysis. Once again, the rate of symptomatic VTE was lower in the HPBS group than nationally, at 17/803 (2.1%) and 31/803 (3.9%), respectively (*p* = 0.040). We next assessed the influence of preoperative factors and operating facility on likelihood of VTE using a univariate logistic regression ([Fig. 2A](#f2){ref-type="fig"}), which identified six factors to be included in the multivariate regression. As shown in [Figure 2B](#f2){ref-type="fig"}, all but one of these parameters was shown to be an independent predictor of VTE incidence; preoperative wound infection (OR = 23.386, *p* = 0.029), ASA class \>2 (OR = 2.316, *p* = 0.034), and disseminated cancer (OR = 4.960, *p* = 0.005) conferred a higher likelihood of symptomatic VTE, whereas current smoking (OR = 0.129, *p* = 0.044) and procedure performed by the HPBS (OR = 0.530, *p* = 0.041) had a protective influence.

![Analysis of VTE risk in the matched cohort. **(A)** Univariate, **(B)** multivariate. \*Indicates a significant result. ASA, American Society of Anesthesiologists; BMI, body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; HPBS, hepatopancreaticobiliary surgery service; HTN, hypertension.](pancan.2020.0002_figure2){#f2}

Secondary analysis {#s007}
------------------

Although not the original focus of this study, a comparison of non-VTE outcomes yielded interesting results. As given in [Table 2](#tb2){ref-type="table"}, the mean total hospital LOS was significantly lower for patients operated on by the HPBS than the national population in both the matched and aggregate cohorts (aggregate: 8.3 ± 6.2 vs. 10.8 ± 9.3 days, *p* \< 0.001; matched: 8.3 ± 6.3 vs. 10.3 ± 7.4, *p* \< 0.001). Furthermore, patients in the HPBS cohort had a significantly lower reoperation rate (aggregate: *p* \< 0.001; matched: *p* = 0.001). In addition, the rate of overall respiratory complications was significantly lower in the HPBS cohort (*p* \< 0.001 in the aggregate, *p* = 0.011 in the matched), as was the rate of myocardial infarction (*p* = 0.008 in the aggregate, *p* = 0.019 in the matched). Deep surgical site infections (SSIs) and wound dehiscence were also significantly lower in both the aggregate and matched HPBS groups. Cardiac arrest and superficial SSI were lower in the HPBS group in the aggregate, but this significance was not confirmed upon matching.

Discussion {#s008}
==========

It has long been suggested that appropriate prescribing patterns and proper adherence to thromboembolism prophylaxis reduce the rate of VTE. Multimodal prophylaxis has been studied extensively in orthopedics and other surgical fields, although to our knowledge no study in pancreatic surgery has previously shown an independent effect of a prophylactic pathway on rates of symptomatic VTE.^[@B22],[@B23]^ Understanding the potential reasons underlying national low outliers in VTE rates has great potential for informing patient care and improving hospital practice.

Our results demonstrate a statistically significant lower rate of VTE events in the HPBS patients than national rates. We sought to determine whether or not the prophylactic pathway of the HPBS may play a role in the low rates of symptomatic VTE seen in those patients. To do so, it was necessary to determine the independent risk factors associated with VTE occurrence in both the HPBS and nationally, and to further determine whether those factors are confounded in any way. We were able to identify 850 HPBS patients in the NSQIP PUF, which afforded us the opportunity to effectively compare HPBS patients with the national subset. Although many factors appeared to be contributors to VTE risk, upon multivariate analysis, it was found that only older age, high BMI, history of a bleeding disorder, and high ASA class independently increase the risk of VTE. Furthermore, we found that Asian race, being a current smoker, and having the procedure performed by the HPBS conferred a significantly lower rate of VTE events. It is unclear why current smoking status has a protective effect, as smoking is a known risk factor for VTE formation.^[@B18]^ That said, VTE risk indices, including the Caprini Risk Index and the Geerts Index, do not include smoking as a stratifying risk factor, suggesting that other factors, such as length of surgery, active cancer, and BMI, are more influential on VTE formation.^[@B17],[@B18]^

Taken together, the results suggest that the difference in VTE rates between the HPBS and national cohorts is not due to patient factors alone and is likely a result of processes of care provided at our institution. In contrast to many other surgical services, all HPBS patients receive the same prophylaxis, which is designed for high-risk individuals, regardless of predisposing risk factors. This is an appropriate method given the high prevalence of VTE risk factors in this patient population (such as extended length of surgery, older age, and malignancy).

The strict VTE prevention pathway ([Fig. 1](#f1){ref-type="fig"}), which the HPBS has followed for the length of the study period, consists of carefully timed utilization of anticoagulation, TED stockings, IPC boots, and ambulation. Uniquely, the HPBS uses both IPCs and TEDs for mechanical prophylaxis in the first 24 h after surgery but discontinues the use of IPCs in favor of TEDs alone for the rest of the hospital stay. The decision to use TED stockings during the entire hospital stay was made by the attending surgeons on the service due to an anecdotally higher adherence than with IPCs; this is a novel practice at our institution. Potentially the most distinctive portion of the HPBS protocol is the use of rotating third-year medical students to encourage patients to meet ambulation goals during their hospital stay (four times a day for 200 feet). The students aid the patients in ambulating and record the ambulation event in the patient\'s room. A hard copy of the number of ambulation events is reviewed by the attending surgeon for each patient at the end of the day. As a result of these measures, the HPBS vastly outperforms other surgical and medical services at our hospital in terms of ambulation adherence, despite having frailer patients. We present the VTE prevention model put forth by the HPBS so that it may serve as a framework for surgical services at other institutions that aim to decrease VTE rates.

A current matter of debate relates to extension of chemoprophylaxis after discharge. During the study period, we did not routinely utilize extended chemoprophylaxis. Guidelines from CHEST released in 2012 suggested extending chemoprophylaxis for 30 days after surgery in cancer patients who are high risk for forming VTE and for whom there is no contraindication to anticoagulation, but there is no recommendation for patients undergoing abdominal surgery for reasons other than malignancy.^[@B24]^ There is still a paucity of evidence regarding extended chemoprophylaxis for VTE prevention in noncancer patients.

Our secondary analysis found that the HPBS patients had a significantly shorter hospital LOS than non-HPBS patients. This may be due to the lower reoperation rates, the lower rates of postoperative complications (including symptomatic VTE), or simply hospital- and service-specific discharge practices. Given the increased negative impact that long periods of immobilization have on VTE formation, the shorter LOS seen in the HPBS patients could be a contributor to the decreased rates of VTE. In addition, a larger proportion of VTEs occurred before discharge in the national cohort than in the HPBS cohort, which may be because non-HPBS patients spend, on average, more time in the hospital, and thus have a greater potential for developing VTE ([Table 2](#tb2){ref-type="table"}).

Although the main focus of this project was to compare the symptomatic VTE rate between the HPBS and the national cohort, many other postoperative complications were found to occur at a lower rate in the HPBS patients, including superficial and deep SSI, wound dehiscence, respiratory complications, and myocardial infarctions. Although not described here, the HPBS has additional protocols for prevention of these adverse events. The lower rates of these specific complications may also be influencing LOS and, therefore, lowering the risk of VTE for HPBS patients. In addition, it has been shown that early ambulation can reduce the risk of postoperative respiratory and cardiac complications, so the HPBS pathway may, in addition to event-specific prophylaxis, account for these lower rates.

Limitations {#s009}
-----------

There are several limitations of this study that need to be acknowledged. The retrospective nature of this study prevents us from speaking to causation, and as such we can only make correlative assessments and conclusions. As with any large database review such as this, there are many potential confounders that are not measured that could influence the outcomes of the study, including cancer metrics, nonsurgical treatments, and use of anticoagulation or antiplatelet therapy. However, the deidentified nature of the NSQIP database precludes more granular data acquisition. Similarly, the NSQIP PUF is an imperfect database due to selective inclusion and reporting criteria. Not all pancreatic cases in the nation are reported in NSQIP, which introduces both selection bias and confounding. Furthermore, adverse events, including symptomatic DVT and PE, are only captured within 30 days of operation, and there is no formal use of routine lower extremity ultrasonography for the detection of DVT or reporting of incidentally discovered VTEs, potentially leading to missed incidences. It is important to note that NSQIP does not capture the prophylactic modalities that were offered to each patient; therefore, it is impossible to determine whether the patients at other institutions received similar or dissimilar inpatient prophylactic regimens as compared with the HPBS patients. Reporting and sharing these prophylactic process measures would be an incredibly powerful tool for guiding institutions in identifying which areas need improvement to reduce rates of VTE.

One line of inquiry that we did not pursue was the consideration of VTE in patients undergoing open versus minimally invasive procedures. Information regarding surgical approach is not included in the main NSQIP PUF, but it is included in the recently implemented pancreas site-specific PUF. This site-specific file is not available for the entirety of the study period, and confining our study to just those years would have excluded two-thirds of our patient population. As such, although we think that this would have been a helpful variable to include, it was not feasible for our cohort.

To identify patients undergoing a pancreatic surgical procedure, we used CPT billing codes. There are inherent limitations to using these codes, as billing procedures are not consistent across institutions, and miscoding may occur. In addition, when querying the PUF for patients undergoing pancreatic procedures, we used only CPT codes utilized by the HPBS. There are a number of other pancreatic surgery-associated codes that are not used by the HPBS; as such, there may be non-HPBS patients with procedures similar to the HPBS cohort whose surgeries were billed under an excluded CPT code, and were, therefore, not included in our study. Although we could have included other CPT codes, we felt that using only HPBS codes would yield the most homogeneous study sample and would ensure that no dissimilar surgeries were included.

Conclusions {#s010}
===========

In following the described multimodal prophylaxis pathway, the HPBS has been consistently identified as a low outlier in VTE rates. We have shown that this designation represents a significantly lower rate of VTE events than the national subset of pancreatic procedures captured in the NSQIP PUF over a large time period. Through the utilization of matching and multivariate analyses, we were able to identify an independent protective effect of the HPBS on VTE incidence, which we believe to be due, at least in part, to the VTE prevention pathway employed by the HPBS, which is diligently adhered to and checked by multiple care providers. The shorter hospital LOS of the HPBS patients, as well as the lower rates of respiratory complications, cannot be understated as well. Further prospective studies are warranted to more accurately determine the parameters associated with VTE events in both the HPBS patients and pancreatic surgery patients at other institutions.
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ACS

:   American College of Surgeons

ASA

:   American Society of Anesthesiologists

BMI

:   body mass index

CPT

:   current procedural terminology

DVT

:   deep vein thrombosis

HPBS

:   hepatopancreaticobiliary surgery service

IPC

:   intermittent pneumatic compression

LOS

:   length of stay

NSQIP

:   National Surgical Quality Improvement Program

OR

:   odds ratio

PE

:   pulmonary embolus

PUF

:   participant user file

SSIs

:   surgical site infections

TED

:   thromboembolic deterrent

VTE

:   venous thromboembolism
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These codes represent excision procedures of the pancreas.
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